HOME >> BIOLOGY >> NEWS
Small-molecule inhibitors of anthrax lethal factor identified

Scientists have identified several compounds that block the activity of a key anthrax protein called lethal factor (LF)--an important first step in developing therapeutics to counter the disease.

Anthrax, a disease caused by the spore-forming bacterium Bacillus anthracis, is most deadly when exposure occurs through inhalation. Prompt diagnosis and antibiotic treatment during the early stages of infection are critical. In many cases, however, antibiotics may not be effective--particularly when bacterial overload causes large amounts of anthrax toxin to be released in the body.

Anthrax toxin consists of three proteins: lethal factor, protective antigen, and edema factor, all of which work in concert to kill host cells. While the exact mechanism of anthrax toxin is not yet well understood, it is clear that developing methods to inhibit toxin assembly and/or function is critically important.

In an article published in this month's issue of Nature Structural and Molecular Biology, investigators from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the National Cancer Institute (NCI), the Burnham Institute, and the Harvard Institutes of Medicine report using a high-throughput assay to screen a group of 1,990 compounds known as the NCI diversity set. The molecular properties of this group are predictive of a larger set of more than 100,000 compounds.

Using a two-stage screening assay, the team identified a number of compounds that inhibited the activity of LF. All inhibitors were further verified by high-performance liquid chromatography and their efficacy was validated in cell culture. Finally, molecular modeling techniques were used to predict structural features that contribute to inhibitor binding and potency.

These techniques revealed a common pharmacophore--a "scaffold" upon which future therapeutics can be built. This pharmacophore will serve as a basis for directing future effo
'"/>

Contact: Caree Vander Linden
Caree.Vander-Linden@amedd.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
22-Jan-2004


Page: 1 2

Related biology news :

1. Small-molecule inhibitors of botulinum neurotoxin identified
2. Chemical genetics identifies SARS inhibitors
3. COX-2 inhibitors and renal damage in obesity-related Type II diabetes
4. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures
5. Study offers new insights into angiogenesis inhibitors
6. COX-2 inhibitors may delay onset of breast cancer
7. Harvard Medical School researchers discover first in a new class of mitosis inhibitors
8. Researchers improve detection of diverse anthrax strains
9. Argonne scientists determine structure of staph, anthrax enzyme
10. Crystal structure for anthrax-cell binding complex
11. TIGR president discusses significance of finding anthrax toxin

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Small molecule inhibitors anthrax lethal factor identified

(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... OncoTAb, Inc., a ... spin-out company, announced today the appointment of physician ... Chief Operating Officer (COO). Cooper brings to OncoTAb ... clinical diagnostic and biotechnology platforms in the fields ... extensive career transcends the field of medical and ...
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... -- Avelas Biosciences, an in vivo cancer ... that it has initiated a Phase 1b study of ... primary, non-recurrent breast cancer undergoing surgery. In commencing the ... Steven Chen , M.D., as vice president of ... study will enroll up to 39 women with stage ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
Cached News: